Bacterial Pneumonia is an indication for drug development with over 110 pipeline drugs currently active. According to GlobalData, preregistered drugs for Bacterial Pneumonia have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Bacterial Pneumonia compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bacterial Pneumonia overview

Bacterial pneumonia is a lung infection caused by bacteria that inflame and fill the air sacs with fluid, pus, and debris. It can affect one or both lungs and make it hard to breathe. Bacterial pneumonia can be mild or severe, depending on the type of bacteria, the person’s age, and their overall health. Some common causes of bacterial pneumonia are Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus. Bacterial pneumonia can be acquired in the community or in a hospital setting. The symptoms of bacterial pneumonia may include cough with yellow, green, or bloody mucus, fever, chills, chest pain, shortness of breath, headache, muscle pain, fatigue, nausea, vomiting, diarrhea, and confusion. Bacterial pneumonia is diagnosed by physical examination, chest X-ray, blood tests, sputum culture, urine test, pulse oximetry, CT scan, or bronchoscopy. Bacterial pneumonia is treated with antibiotics, oxygen therapy, fluids, rest, and pain relievers. Bacterial pneumonia can be prevented by getting vaccinated against pneumococcal pneumonia and other infections, washing hands frequently, avoiding smoking and alcohol, eating healthy foods, exercising regularly, and staying away from sick people.

For a complete picture of PTSR and LoA scores for drugs in Bacterial Pneumonia, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.